Pharmacology Policy Institute (PPI)
In response to COVID-19, my colleagues and I have launched several new and urgent projects. The purpose of this letter is to seek charitable donations and raise initial funding for immediate research and advocacy to staff the Pharmacology Policy Institute, a 501(c)(3) non-profit public benefit corporation, which will sponsor these coronavirus pandemic projects.
There are currently three projects that the Pharmacology Policy Institute (PPI) has launched.
1. Urgent and Immediate Health Policy Research and Advocacy to Ensure the Availability of Intravenous Ascorbic Acid [(IVAA) or (IV Vitamin C)] in Hospitalized Patients
UPDATE April 7, 2020
FOR IMMEDIATE RELEASE: April 6, 2020 New York, NY: Five leading critical care specialists, who together have formed the Front Line COVID-19 Critical Care Consortium, have released a protocol for treating patients who arrive in hospitals with COVID-19. Based on available research, the experience in China reflected by the Shanghai expert commission, and their decades-long professional experiences in Intensive Care Units around the country, the five experts strongly urge fellow physicians to immediately adopt a change in strategy by delivering powerful therapies earlier in the disease course, prior to admission to the ICU or the need for a mechanical ventilator. Based on early experiences with this more aggressive approach, they predict that early adoption of the protocol will reduce ICU admissions, obviate the need for mechanical ventilators, and most importantly, save many lives.
March 23, 2020
No issue is more pressing than the rising death rate in hospitalized patients in the United States, escalating rapidly as this is being written. Last week, our practice was swept into the issues of the acute management of COVID-19 respiratory failure by a critically ill patient we were consulted on in New York State.
I quickly reacquainted myself with Paul Marik, M.D., the leading U.S. academic proponent for the advocacy of intravenous ascorbic acid, which he believes can be lifesaving in the treatment of COVID-19 patients. He derived his protocols from his extensive work with IVAA in sepsis, his understanding of its recent, routine and successful use in parts of China for COVID-19, and his preliminary success with it in his first COVID-19 cases in Virginia.
We intend to continue my research on an urgent basis, speaking with Dr. Marik and the principal investigators of the Chinese and Italian studies registered on clinical trials, to assess the availability of IVAA here in California, and to formally publish an urgent health policy article in the peer-reviewed literature on this topic.
The Pharmacology Policy Institute needs immediate support to accomplish these goals. I deeply thank you for your consideration of this request.
2. Buprenorphine Availability in the Face of the COVID-19 Pandemic
After one of my patients expressed deep concerns about the future availability of buprenorphine, given the possible disruption of pharmaceutical supply chains, I have begun making efforts with several pharmacies to set aside additional supplies. The probabilities of buprenorphine shortage and subsequent harm to patients may be greater than those associated with other pharmaceuticals.
Neither withdrawal nor the alternative use of other opiates, with higher abuse potential, are safe, humane, or acceptable from a public health standpoint, particularly during a pandemic, with widespread suffering already prevalent.
3. Enhancement of Immune Defenses Against COVID-19 Illness in Non-Hospitalized Patients
There is limited reliable information on the prevention of COVID-19 infection through lifestyle, diet, mindfulness, exercise, and nutritional supplementation. Our immune systems need a rapid upgrade.
One approach, that of the Andrew Weil Center for Integrative Medicine at the University of Arizona, appears to be the first well-organized effort in this regard. We project there will be others soon. We would leverage our collective experience to enhance the emerging knowledge in these areas for the prevention and the treatment of non-hospitalized COVID-19 patients.